Ocular Therapeutix reports inducement grant under Nasdaq listing rule

Ocular Therapeutix (OCUL) granted inducement awards to one newly hired non-executive employee. The award was made as an inducement material to the individual’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of November 3, 2025, and consist of a non-statutory stock option to purchase up to 1,100 shares of Ocular’s common stock and a restricted stock unit award representing the right to receive 367 shares of Ocular’s common stock. The stock option has an exercise price of $11.47 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. The stock option has a ten-year term and is scheduled to vest over four years, with 25% of the original number of shares vesting on October 20, 2026, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The restricted stock unit award is scheduled to vest over three years, in equal annual installments, with the first annual installment vesting on November 3, 2026, and subject to the recipient’s continued service to Ocular through the applicable vesting dates. The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.